Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001
Advertisement

Related Content

Novartis Consumer Health Reshuffled, Functional Foods On Sales Block
Novartis Consumer Health Reshuffled, Functional Foods On Sales Block
Novartis Consumer Health Reshuffled, Functional Foods On Sales Block
Lotrimin Ultra Antifungal Switch Approved By FDA
Lotrimin Ultra Antifungal Switch Approved By FDA
Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley
Bayer Aspirin Migraine Gets FDA Nod; Midol May Be On Deck
Perrigo Riding High On Wall Street As ANDA Approvals Resume
Prilosec OTC Launch By July 2002 Predicted By P&G's Lafley
Tavist Line Extensions Include NDA, Monograph Products

Topics

Advertisement
UsernamePublicRestriction

Register

PS093583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel